And as we approach a new year, University Diaries will continue to pursue the links between corporate-sponsored psychiatry research at some of America’s most high-profile universities, and the destructive, expensive pathologizing of the American public. ““[T]he increase in diagnoses [of mental illness in America] is a boon to pharmaceutical manufacturers,” notes a Forbes writer. “The new generation of psychoactives has displaced cholesterol-reducing medications as the biggest-selling class of drugs in the U.S.” It wouldn’t be happening without Harvard’s Joseph Biederman and the rest of the COI university crew.
There’s hope. But only a little bit of hope. The battle has to be fought hard, and we’ll probably lose.
But anger over the money culture behind pharma investment, and at the damage being done to our children by anti-psychotics, will no doubt find greater focus and expression this coming year. UD will of course follow the story.